et al. Endocrinol. iapon. December 1984 Hall et al., 1972; Irie et al., 1972; Kumahara et al., 1975) . Pressure on the normal pituitary gland by a pituitary tumor or the effect on TSH secretion of excessive secretion of GH is considered to be the cause of the decreased TSH secretion in acromegalic patients. In this investigation we report the changes in TSH secretion in acromegalic patients before and after adenomectomy and compared the results with normal subjects and patients with prolactinoma.
Materials and Methods

Subjects
Six patients with acromegaly (patient number 1-6) were studied ( 
Results
The high basal level of serum GH in each acromegalic patient decreased to a level less than 5 ng/ml after adenomectomy. The levels of GH secretion after insulin administration to the patients before and after adenomectomy are shown in Fig. 1 . The response of GH to insulin hypoglycemia was not observed in any of the subjects before or after surgery. Fig. 2 levels of TRH-stimulated TSH were significantly lower in the acromegalic patients than in those of normal subjects (p<0.01) and the patients with prolactinoma (p<0.05). The levels of TRH-stimulated TSH in the six acromegalic patients before, about two weeks after, and three months after adenomectomy are shown in Fig. 4 . Each patient showed a stronger response to TRH after, rather than before, adenomectomy. Only patient No.2 showed a weaker response two weeks after the operation. In three of five patients studied, the serum T3 level before adenomectomy was lower than the lowest limit for those of normal subjects. Serum T3 concentrations increased after the operation in all patients studied except patient No.1, whose serum T3 level was within the normal range initially (Fig. 5) . The serum T4 level and free T4 index did not change significantly after adenomectomy in each of the five patients studied (Table 1) . T3-uptake levels were all within the normal range both before and after surgical treatment, although each increased slightly (Fig. 5) Some acromegalic patients with a normal serum GH level continue to show an abnormal GH response to TRH even after surgical therapy (Samaan et al., 1974; Giovanelli et al., 1976) . Because the serum GH response to TRH is believed to be mediated by a direct pituitary action of TRH which probably is exerted on abnormal receptors of the adenomatous somatotrophs (Faglia et al., 1973; Giustina et al., 1974; Hoyte and Martin, 1975; De Camilli et al., 1976) , the patients who persistently respond abnormally to TRH are not to be regarded. as cured. The disappearance of the abnormal GH response to TRH after surgery probably indicates satisfactory treatment of acromegaly (Faglia et al., 1978) . In this study, the basal serum GH level dropped to less than 5 ng/ml after surgery and abnormal GH response to TRH disappeared (Fig. 2) . These findings indicate that a nearly complete resection of the pituitary adenoma was obtained. Serum GH did not increase with insulin hypoglycemia even after surgery in these patients (Fig. 1) . These results indicate that GH secretion from the intact part of the pituitary gland is impaired in acromegalic patients. A decrease in TSH has been observed more frequently in acromegalic patients (68%) than in patients with prolactinoma (36%) (Miyai and Uozumi, 1976) . Although the response of TSH to TRH was decreased before adenomectomy in our patients, the TSH response improved after the operation. The secretion of TSH is regulated mainly by the level of circulating thyroid hormones and by TRH.
Somatostatin infusion has been found to suppress TSH secretion in normal subjects (Hall et al., 1973; Siler et al., 1974; Weeke et al., 1974) and in patients with hypothyroidism (Lucke et al., 1975) . Elevation of the basal TSH level following administration of somatostatin antiserum has been observed in rats Ferland et al., 1976) . These findings indicate that somatostatin has an inhibitory effect on TSH secretion.
The mechanisms by which TSH secretion decreases in acromegaly are not clarified yet. Possible explanations include (i) an adenoma may decrease the function of thyrotrophs by a pressure upon a normal pituitary gland, (ii) the thyroid gland that is often hypertrophic in acromegalic patients may secrete excessive thyroid hormones and result in the suppression of TSH secretion by negative feedback, and (iii) a raised hypothalamic somatostatin level due to increased GH secretion from the pituitary adenoma of acromegalic patients may inhibit TSH secretion, as well as GH secretion from the intact part of the pituitary gland.
If the first hypothesis is correct, the TRH-stimulated TSH concentration in patients with prolactinoma should be as low as in acromegalic patients. However, the patients with prolactinoma showed a stronger TSH response to TRH than the acromegalic patients, as shown in Fig. 3 . The second possibility is unlikely because the serum T3 and T4 levels were normal or subnormal in all the patients except patient No.6 (Fig. 5) . The secretion of GH and TSH from the intact pituitary gland may be inhibited by increased somatostatin secretion from the hypothalamus.
The excessive GH that is secreted from a tumor may suppress GRF secretion and accelerate somatostatin secretion from the hypothalamus (Fig. 6) . It is also possible that the improvement in TSH secretion after surgery, when the GH level dropped to below 5ng/ml, may be due to a release from the inhibitory effect of somatostatin.
There have been many reports which support the last hypothesis. Berelowitz et al. (1981) reported that the somatostatin content in the hypothalamus was distinctly increased and the capability of somatostatin secretion in vitro was increased compared with controls when GH was administered to rats.
However, the ability to secrete somatostatin from the hypothalamus decreased when an adenomectomy was performed or GH antiserum was administered. Furthermore, it has been shown that the somatostatin concentration in pituitary portal blood rises when GH is administered to the third ventricle of the rat (Chihara et al., 1981) . These results indicate that at least some of the negative feedback mechanisms involved in GH secretion are caused by a variation in hypothalamic somatostatin. Lippe et al. (1975) reported that in four of six children with idiopathic GH deficiency who became hypothyroid during treatment with exogenous GH, TRH-stimulated TSH concentrations were either absent or reduced.
In this context it has been postulated by Hall et al. (1978) that GH may induce the synthesis and release of somatostatin via a short-loop positive feedback, and that the increased endogenous level of somatostatin would in turn suppress both GH and TSH release.
Three of the six patients had a serum T3 level lower than normal (Fig. 5) . We could not find a correlation between the serum T3 level and the response of TSH to TRH. Klijn et al. (1980) compared the functions of the pituitary-thyroidal axis in acromegalic patients and patients with hyperprolactinemia and a pituitary tumor. They found a positive correlation between the TRH-stimulated TSH concentration and T3 level but not between the TRH-stimulated TSH concentration and the T4 level in the patients with prolactinoma, while in the acromegalic patients there was no correlation between TSH reserve and the level of T3 or T4. Serum T3, T4, T3-uptake levels and free T4 indices did not change significantly after adenomectomy as compared with those before the operation in five of the six patients studied, although all of the patients were almost completely cured by the operation (Table 1 and Fig. 5) . Therefore, the impaired TSH secretion may scarcely affect thyroid function in acromegalic patients.
The decreased TSH secretion in acromegalic patients may be due to increased secretion of hypothalamic somatostatin caused by an excess of GH. If one can measure the levels of somatostatin and GRF in the hypothalamus and pituitary portal blood in acromegalic patients, it will be helpful in verifying this.
